Cerevance
Founded 2016 Β· 9 known investors
Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS. It uses a proprietary human brain tissue profiling platform (NETSseq) and advances candidates such as solengepras (CVN424), CVN293, and CVN766 through clinical trials.
BiotechDeep TechHealthtech
Founders & leadership
CT
Craig ThompsonChief Executive Officer
SV
Sagar VaidyaChief Medical Officer
CA
Carrie Ann CookChief Business Officer
Investors Β· 9
Foresite Capitalβ verifiedLarkspur
GV (Google Ventures)β verifiedMountain View Β· $250K β $50M
Dementia Discovery Fundβ verifiedLondon
SV Life Sciencesβ verifiedBoston
Dementia DiscoveryLondon
Lightstone VenturesPortola Valley
SV Health InvestorsBoston Β· $1M β $20M
Agent CapitalreportedWaltham
Dolby Family VenturesreportedSan Francisco
Frequently asked questions
- What does Cerevance do?
- Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS. It uses a proprietary human brain tissue profiling platform (NETSseq) and advances candidates such as solengepras (CVN424), CVN293, and CVN766 through clinical trials.
- Who are Cerevance's investors?
- Cerevance's investors include Foresite Capital, GV (Google Ventures), Dementia Discovery Fund, SV Life Sciences, Dementia Discovery, Lightstone Ventures, SV Health Investors, Agent Capital and 1 more.